Dr. Lea is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2622- Is this information wrong?
Summary
- Dr. Jayanthi Lea is the Division Chief of Gynecologic Oncology at University of Texas Southwestern Medical Center in Dallas, TX and is affiliated with multiple hospitals in the area, including University of Texas Southwestern Medical Center, and William P. Clements, Jr. University Hospitals and Parkland Health & Hospital System. She is an expert in ovarian, endometrial, cervical and vulvar cancer and is nationally recognized for her expertise in radical pelvic surgery and minimally invasive surgery. She received her medical degree from Brody School of Medicine at East Carolina University and has been in practice 21 years. She has more than 80 publications and over 500 citings.
Education & Training
- University of Texas Southwestern Medical CenterFellowship, Gynecologic Oncology, 2000 - 2004
- U Texas Med Sch2004
- OhioHealth/Riverside Methodist HospitalResidency, Obstetrics and Gynecology, 1996 - 2000
- Brody School of Medicine at East Carolina UniversityClass of 1996
Certifications & Licensure
- TX State Medical License 2000 - 2025
- NC State Medical License 2008 - 2024
- OH State Medical License 1997 - 2000
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
- FACSFellow
Awards, Honors, & Recognition
- Best Doctors 2022
- Best Doctors - Dallas 2022
- Texas Super Doctors 2022
- Join now to see all
Clinical Trials
- Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer Start of enrollment: 2008 May 01
- Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer Start of enrollment: 2012 Feb 01
- Randomized Phase II Study of Intravenous 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine® NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and S Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Survivorship Care for Women Living With Ovarian Cancer: Protocol for a Randomized Controlled Trial.Kvale, E., Phillips, F., Ghosh, S., Badr, H., Saleem, N., Ward, R., Balasubramanian, B., Lea, J., Hoppenot, C., Costales, A., Sunde, J., Nwogu-Onyemkpa, E.> ;JMIR Research Protocols. 2024 Feb 9
- Social determinants of health in uterine carcinosarcoma.Aroche Gutierrez, L., McIntire, D., Miller, D. S., Lea, J., LoCoco, S., Miller, D.> ;Gynecologic Oncology. 2024 Feb 2
- Quantifiable TCR repertoire changes in pre-diagnostic blood specimens among high-grade ovarian cancer patients.Xuexin Yu, Jianfeng Ye, Cassandra A Hathaway, Shelley Tworoger, Jayanthi Lea, Bo Li> ;Biorxiv. 2023 Oct 17
- Join now to see all
Press Mentions
- New Study Shows Increasing U.S. Cases of Uterine Cancer Overall and Higher Mortality in Black WomenJuly 25th, 2022
- New Biomarkers and Flaw Found in Ovarian CancerAugust 3rd, 2021
- Newly Developed Nanoparticle Vaccine Immunotherapy Targets Multiple Cancer TypesApril 25th, 2017
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Other Languages
- Tamil
Hospital Affiliations
- Parkland HealthDallas, Texas
- University of Texas Southwestern Medical CenterDallas, Texas
- William P. Clements, Jr. University HospitalDallas, Texas
External Links
- UT Southwesternhttp://profiles.utsouthwestern.edu/profile/45963/jayanthi-lea.html
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: